BridgeBio Pharma - Ada Patient Finder Analysis

Analysis Date: March 11, 2026
Analyst: Ada Cockpit Research Team

Executive Summary

BridgeBio Pharma operates a portfolio of one approved drug (ATTRUBY) and three late-stage Phase 3 candidates targeting rare genetic diseases with significant underdiagnosis. This analysis evaluates each asset for Ada Patient Finder partnership suitability.

Key Finding: ATTRUBY for ATTR-CM represents the highest-value immediate opportunity, with massive underdiagnosis (98.3% of eligible HF patients untested), 1.3-year average diagnostic delay, and $1.97B peak sales potential. Combined addressable opportunity across all four drugs: $15-30M annual Ada revenue at 1-5% market penetration.

Portfolio Overview

Drug	Indication	Tier	Fit Score	Addressable Undiagnosed (USA)	Ada Revenue Opportunity (1% / 5%)
ATTRUBY (acoramidis)	ATTR-CM	Tier 1 Pursue Aggressively	8.5/10	80,000	$9.76M / $48.8M
Encaleret (BBP-711)	ADH1	Tier 2 Pursue	6.5/10	3,500	$525K / $2.63M
Infigratinib	Achondroplasia	NO Not Suitable	2.0/10	0 (diagnosed at birth)	$0
BBP-418 (ribitol)	LGMD2I/R9	Tier 3 Opportunistic	4.5/10	450	$106K / $532K

Drug 1: ATTRUBY (acoramidis) - TIER 1

Indication: ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Market Opportunity

Addressable Undiagnosed (USA): 80,000 patients

Addressable Undiagnosed (DACH): 16,000 patients

Addressable Undiagnosed (ROW): 63,650 patients

Revenue Metrics

WAC (USA): $244,000/year

Net Revenue per Patient: $122,000/year (USA)

PF Fee per Patient: $12,200 (10% of first-year revenue)

2025 Revenue: $362.4M

Peak Sales Estimate: $1.97B (2030)

Diagnostic Landscape

Underdiagnosis Rate: 90-95% (only 1.7% of HF patients tested)
Diagnostic Delay: Median 490 days (1.3 years) from HF diagnosis to ATTR-CM diagnosis
Common Misdiagnoses: Hypertensive heart disease, coronary artery disease, HCM
Symptoms: Unexplained dyspnea, HF symptoms, atrial fibrillation, carpal tunnel syndrome
Diagnosing Specialist: Advanced HF cardiologist or amyloidosis specialist

Ada Patient Finder Fit

Dimension	Score	Assessment
Ada Surface Ability	8/10	HF symptoms + red flags (carpal tunnel, neuropathy, unexplained LVH) are highly identifiable
Company Motivation	9/10	BridgeBio needs 5-10x current volumes to hit peak sales; underdiagnosis is existential barrier
Market Size	10/10	Massive underdiagnosis (112K-190K undiagnosed Americans), high revenue per patient
Diagnostic Delay	9/10	1.3-year median delay is substantial; 3.4-6.1 years from symptom onset
Overall Fit Score	8.5/10	TIER 1: PURSUE AGGRESSIVELY

Ada Revenue Opportunity

Region	1% Penetration	5% Penetration
USA	$9.76M/year	$48.8M/year
DACH	$2.54M/year	$12.72M/year
ROW	$7.0M/year	$35.0M/year
TOTAL GLOBAL	$19.3M/year	$96.5M/year

Competitive Landscape

Pfizer Vyndaqel/Vyndamax (tafamidis): Market leader, $5.45B revenue (2024), ~70-80% market share
Alnylam Amvuttra: Approved 2025, projected $4.4B by 2030
ATTRUBY positioning: Near-complete TTR stabilization (≥90%), $244K WAC vs Vyndaqel $268K

Pitch Hook

"BridgeBio: Only 1.7% of heart failure patients are tested for ATTR-CM, yet screening studies show 6-8% prevalence in HFpEF populations—that's 112,000-190,000 undiagnosed Americans who could benefit from ATTRUBY. With a median diagnostic delay of 490 days from HF diagnosis and peak sales targets requiring 5-10x current volumes, Ada Patient Finder can systematically identify high-risk HF patients using symptom patterns and clinical red flags (HFpEF + carpal tunnel history, unexplained LVH), directing them to confirmatory PYP scans. At $122K net revenue per patient and 10% PF fees, every 1% of addressable patients found generates $9.8M annual Ada revenue."

Drug 2: Encaleret (BBP-711) - TIER 2

Indication: ADH1 (Autosomal Dominant Hypocalcemia Type 1)

Market Opportunity

Addressable Undiagnosed (USA): 3,500 patients

Total ADH1 Prevalence (USA): 3.7-3.9 per 100,000 (~12,600 total)

Underdiagnosis Rate: 80%

Revenue Metrics

Estimated WAC: $300,000/year

Est. Net Revenue per Patient: $150,000/year (USA)

PF Fee per Patient: $15,000

Status: Phase 3, NDA filing H1 2026

Diagnostic Landscape

Diagnostic Delay: Average 9 years from first hypocalcemia to genetic confirmation
Common Misdiagnoses: Idiopathic hypoparathyroidism, vitamin D deficiency, epilepsy
Symptoms: Seizures (50% of symptomatic), severe muscle cramps, paresthesia, fatigue
Diagnosing Specialist: Endocrinologist + genetic testing (CASR mutations)

Ada Patient Finder Fit

Dimension	Score	Assessment
Ada Surface Ability	7/10	Distinctive symptom patterns (seizures + muscle cramps in young patients)
Company Motivation	6/10	80% underdiagnosis creates need; small market limits investment appetite
Market Size	4/10	Small addressable population (~3,500 US symptomatic)
Diagnostic Delay	8/10	9-year delay is substantial
Overall Fit Score	6.5/10	TIER 2: PURSUE

Ada Revenue Opportunity

Region	1% Penetration	5% Penetration
USA	$525K/year	$2.625M/year
DACH	$115.5K/year	$577.5K/year
ROW	$216K/year	$1.07M/year
TOTAL GLOBAL	$857K/year	$4.27M/year

Strategic Positioning

First-in-class therapy - No competition, premium pricing opportunity
Pre-launch advantage: Build diagnosis infrastructure before 2027 approval
Bundling opportunity: Package with ATTRUBY in portfolio negotiation

Drug 3: Infigratinib - NOT SUITABLE

Indication: Achondroplasia (Dwarfism)

Market Assessment

Addressable Undiagnosed: 0 patients

Diagnostic Delay: None (diagnosed at birth/infancy)

Fit Score: 2.0/10

Why Not Suitable

Achondroplasia is diagnosed at birth or in infancy based on distinctive physical features
Prenatal detection in 63-71% of cases via ultrasound
No undiagnosed population exists - patients are identified by obstetricians and pediatricians
Commercial challenge is market share vs BioMarin Voxzogo, not patient finding
Ada symptom checker has no role in diagnosis of congenital skeletal dysplasias

Recommendation

DO NOT PURSUE. Ada Patient Finder is not aligned with BridgeBio's commercial needs for infigratinib. The opportunity is treatment uptake among already-diagnosed patients, not patient identification.

Drug 4: BBP-418 (ribitol) - TIER 3 (Opportunistic)

Indication: LGMD2I/R9 (Limb-Girdle Muscular Dystrophy Type 2I/R9)

Market Opportunity

Addressable Undiagnosed (USA): ~450 patients

Estimated Prevalence: 2-5 per million (ultra-orphan)

Underdiagnosis Rate: 60-70%

Revenue Metrics

Estimated WAC: $350,000-$500,000/year

Est. Net Revenue per Patient: $212,500/year (USA)

PF Fee per Patient: $21,250

Ada Revenue Opportunity

Region	1% Penetration	5% Penetration
USA	$106K/year	$532K/year
DACH	$12.75K/year	$76.5K/year
ROW	$22K/year	$88K/year
TOTAL GLOBAL	$141K/year	$697K/year

Ada Patient Finder Fit

Dimension	Score	Assessment
Ada Surface Ability	5/10	Progressive muscle weakness recognizable; very rare condition creates high false positive risk
Company Motivation	5/10	Ultra-orphan - every patient matters, but natural referral pathways exist
Market Size	2/10	Very small addressable population (~450 US, ~700 global)
Diagnostic Delay	6/10	Multi-year delay exists
Overall Fit Score	4.5/10	TIER 3: OPPORTUNISTIC

Strategic Recommendation

Pursue only if:

Bundled with ATTRUBY/encaleret partnership (portfolio deal)
BridgeBio expresses strong interest in diagnosis expansion
Minimal incremental effort (leverage existing neuromuscular symptom pathways)

Do not pursue as standalone opportunity. Revenue potential ($141K-$697K globally) does not justify dedicated resources.

Strategic Recommendations

1. Lead with ATTRUBY (Tier 1)

Massive underdiagnosis (98.3% of HF patients untested)
$9.76M-$48.8M Ada revenue potential (USA alone, 1-5% penetration)
BridgeBio needs 5-10x volume growth to hit $1.97B peak sales
Clear Ada capability: HF symptoms + red flags identifiable
Action: Position Ada as systematic HFpEF screening tool; 60-day pilot with 3-5 advanced HF centers

2. Bundle Encaleret (Tier 2)

80% underdiagnosed, 9-year diagnostic delay
$857K-$4.27M Ada revenue potential (global, 1-5%)
Pre-launch opportunity to build diagnosis infrastructure
Action: Package with ATTRUBY in portfolio negotiation; target pediatric endocrinologists

3. Exclude Infigratinib

No undiagnosed population (diagnosed at birth)
Commercial challenge is market share, not diagnosis
Action: DO NOT PURSUE

4. Opportunistic: BBP-418 (Tier 3)

Very small revenue opportunity ($141K-$697K global)
Only pursue if bundled with ATTRUBY/encaleret or BridgeBio requests
Action: Include as add-on in portfolio deal if requested

Negotiation Framework

Element	Recommendation
Lead Asset	ATTRUBY (Tier 1)
Bundle Opportunity	ATTRUBY + Encaleret (combined $10.3M-$51.4M at 1-5%)
Exclude	Infigratinib (not suitable)
Add-on if Requested	BBP-418 (minimal incremental effort)
Pricing Model	10% of first-year net revenue per patient found
Volume Tiers	Discount at >500 patients/year found
Portfolio Discount	15% if bundling ATTRUBY + Encaleret
Proof of Concept	90-day pilot with ATTRUBY in 3-5 advanced HF centers